3.
Selected phase III trials addressing the role of chemotherapy in stage IVB, recurrent or persistent CC
| Author (ref.) | No. of patients | Histology | Reference regimen | Regimen investigated | Survival (months) |
| CC, cervical cancer; SCC, squamous cell carcinoma; ADC, adenocarcinoma; ADS, adenosquamous carcinoma; CDDP, cisplatin; PTX, paclitaxel; TOP, topotecan; 1, MVAC arm (Methotrexate 30 mg/m2 d 1, 15, 22 + vinblastine 3 mg/m2 d 2, 15, 22 + doxorubicin 30 mg/m2 d 2 + cisplatin 70 mg/m2 d 2, q 21 d) closed prematurely due to severe adverse effect; GEM, gemcitabine; VNR, vinorelbine; Bev, bevacizumab; CBDCA, carboplatin; PFS, progression-free survival; OS, overall survival; NS, not significant. | |||||
| Moore et al.
(2004) (53) |
169 | SCC | CDDP 50 mg/m2 q 21 d |
CDDP 50 mg/m2 +
PTX 135 mg/m2/24 h q 21 d |
PFS 2.8 vs. 4.8
(P<0.01) |
| Long et al.
(2005) (54) |
179 | SCC,
ADC, ADS |
CDDP 50 mg/m2
q 21 d |
CDDP 50 mg/m2 +
TOP 0.75 mg/m2 d 1–3, q 21 d MVAC1 |
PFS 2.9 vs. 4.6
(P<0.01) |
| Monk et al.
(2009) (55) |
204 | SCC,
ADC, ADS |
CDDP 50 mg/m2 +
PTX 135 mg/m2/24 h q 21 d |
CDDP 50 mg/m2 +
TOP 0.75 mg/m2 d 1–3, q 21 d CDDP 50 mg/m2 + GEM 1,000 mg/m2 d 1, 8 CDDP 50 mg/m2 + VNR 30 mg/m2 |
PFS 5.8 vs. 4.6 vs. 4.7
vs. 4.0 (NS) |
| Tewari et al.
(2014) (56,57) |
452 | SCC,
ADC, ADS |
CDDP 50 mg/m2 +
PTX 135 mg/m2/24 h or 175 mg/2 3 h, q 3 w, or TOP 0.75 mg/m2 d 1–3 + PTX 175 mg/m2/3 h, d 1 q 3 w |
CDDP 50 mg/m2 +
PTX 135 or 175 mg/m2 + Bev 15 mg/kg q 3 w, or TOP 0.75 mg/m2 d 1–3 + PTX 175 mg/m2, d 1 + Bev 15 mg/kg q 3 w |
OS 16.8 Bev + vs.
13.3 Bev– (P=0.007) |
| Kitagawa et al.
(2015) (58) |
244 | SCC,
ADC, ADS |
CDDP 50 mg/m2 +
PTX 135 mg/m2/24 h, q 3 w |
CBDCA (AUC 5) +
PTX 175 mg/m2/3 h q 3 w |
PFS 18.3 vs. 17.5
(NS) |